Emerging Drugs And Targets For Parkinsons Disease at Meripustak

Emerging Drugs And Targets For Parkinsons Disease

Books from same Author: Ana Martinez and Carmen Gil

Books from same Publisher: Royal Society Of Chemistry

Related Category: Author List / Publisher List


  • Retail Price: ₹ 19007/- [ 15.00% off ]

    Seller Price: ₹ 16156

Sold By: T K Pandey      Click for Bulk Order

Offer 1: Get ₹ 111 extra discount on minimum ₹ 500 [Use Code: Bharat]

Offer 2: Get 15.00 % + Flat ₹ 100 discount on shopping of ₹ 1500 [Use Code: IND100]

Offer 3: Get 15.00 % + Flat ₹ 300 discount on shopping of ₹ 5000 [Use Code: MPSTK300]

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

Free Shipping Available



Click for International Orders
  • Provide Fastest Delivery

  • 100% Original Guaranteed
  • General Information  
    Author(s)Ana Martinez and Carmen Gil
    PublisherRoyal Society Of Chemistry
    ISBN9781849736176
    Pages402
    BindingHardback
    LanguageEnglish
    Publish YearJuly 2013

    Description

    Royal Society Of Chemistry Emerging Drugs And Targets For Parkinsons Disease by Ana Martinez and Carmen Gil

    Affecting over 1.5 million people across the world, Parkinson's disease is a progressive neurological condition characterized, in part, by the loss of dopaminergic neurons in the substantia nigra pars compacta. It affects 1.5% of the global population over 65 years of age. As life expectancy is increasing, over the next few years the number of patients with Parkinson's disease will grow exponentially. To date, there are no available treatments that are capable of curing Parkinson's disease, and the current goal of therapy, dopamine replacement strategies, is to reduce symptoms. After several years of disease progression, treatment is complicated by the onset of motor fluctuations and dyskinesias. This information reveals the great importance and social need of finding an effective therapeutic intervention for Parkinson's disease. This exemplary new book reviews some of the most outstanding examples of new drugs currently in pharmaceutical development or new targets currently undergoing the validation process to try to reach the Parkinson's drug marke...